The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the time between initiation and completion of the FIDELIO-DKD and FIGARO-DKD trials, numerous rigorous clinical trials demonstrated large kidney and cardiovascular bene fi ts of SGLT2i (Section 1.3 above), and SGLT2i became an established fi rst-line treatment for T2D with CKD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prioritization of SGLT2i therapy in high-risk patients such as those with CKD is consistent with the recommendations from other professional societies including the American College of Cardiology (ACC), 142 the joint statement by the ADA and the European Association of the Study of Diabetes (EASD), 143 and the joint guideline by the European Society of Cardiology (ESC) and EASD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
ResultDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M., & Glotov, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186842 · Cited by 74
Evans, M., Welsh, Z., & Seibold, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01253-9 · Cited by 67
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 70
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
Rajan, N., Duggan, E. W., Abdelmalak, B., Butz, S. F., Rodriguez, L. V., Vann, M. A., & Joshi, G. P. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006791 · Cited by 75
Coronell‐Tovar, A., Pardo, J. P., Rodríguez‐Romero, A., Sosa‐Peinado, A., Vásquez-Bochm, L. X., Cano‐Sánchez, P., Álvarez‐Añorve, L. I., & González‐Andrade, M. (2024) · FEBS Letters · doi:10.1002/1873-3468.14901 · Cited by 72
Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy for Remission of Type 2 Diabetes
Castellana, M., Procino, F., Biacchi, E., Zupo, R., Lampignano, L., Castellana, F., Sardone, R., Palermo, A., Cesareo, R., Trimboli, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa737 · Cited by 69
Diabetes Mellitus and Heart Failure
Triposkiadis, F. K., Xanthopoulos, A. V., Bargiota, Α., Kitai, T., Katsiki, N., Farmakis, D. T., Skoularigis, J. S., Starling, R. C., & Iliodromitis, E. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163682 · Cited by 73
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 73
Wu, Y., Min, H., Li, M., Shi, Y., Ma, A., Han, Y., Gan, Y.-D., Guo, X., & Sun, X. (2023) · BMC Public Health · doi:10.1186/s12889-023-16066-z · Cited by 71
Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
Harris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 63
Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
Li, Y., Yang, X., Yan, P., Sun, T., Zeng, Z., & Li, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704666 · Cited by 64
Kibirige, D., Sekitoleko, I., Lumu, W., Jones, A. G., Hattersley, A. T., Smeeth, L. L., & Nyirenda, M. (2022) · Diabetologia · doi:10.1007/s00125-021-05644-8 · Cited by 59
Yang, S., Yu, B., Yu, W., Dai, S., Feng, C., Shao, Y., Zhao, X., Li, X., He, T., & Jia, P. (2023) · Nature Communications · doi:10.1038/s41467-023-42423-y · Cited by 67
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 65
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, C. P., Hall, Y. N., Trikudanathan, S., Tuttle, K. R., Hirsch, I. B., de Boer, I. H., & Zelnick, L. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108204 · Cited by 58
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Hofherr, A., Williams, J. H., Gan, L., Söderberg, M. P., Hansen, P., & Woollard, K. J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02794-8 · Cited by 61
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 58
Birkeland, K. I., Bodegård, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14189 · Cited by 56
Ma, Q., Zhao, X., Shi, A., & Wu, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s284357 · Cited by 57
arif, M., O’Donovan, M. R., Sezgin, D., Moloney, E., Rodríguez‐Laso, Á., Liew, A., & Ó’Caoimh, R. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.895313 · Cited by 59
Farmer, R. E., Beard, I., Raza, S. I., Gollop, N. D., Patel, N., Tebboth, A., McGovern, A. P., Kanumilli, N., & Ternouth, A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.12.015 · Cited by 55
Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
Kuma, A., & Kato, A. (2022) · Nutrients · doi:10.3390/nu14183787 · Cited by 67
EUROASPIRE IV & V Investigators, Ferrannini, G., De Bacquer, D., Vynckier, P., De Backer, G., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Tuomilehto, J., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01233-6 · Cited by 54
Llewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54
Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Díaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 53
Self-citationDennis, J., Young, K., McGovern, A. P., Mateen, B. A., Vollmer, S. J., Simpson, M. D., Henley, W., Holman, R. R., Sattar, N. A., Pearson, E. R., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00174-1 · Cited by 55
Martemucci, G., Khalil, M., Luca, A. D., Abdallah, H., & D‘Alessandro, A. G. (2024) · Metabolites · doi:10.3390/metabo14060327 · Cited by 60
Minimally and non-invasive glucose monitoring: the road toward commercialization
Min, S. Q., Geng, H., He, Y., Xu, T., Liu, Q., & Zhang, X. (2025) · Sensors & Diagnostics · doi:10.1039/d4sd00360h · Cited by 56
Falkentoft, A. C., Andersen, J., Malik, M. E., Selmer, C., Gæde, P., Stæhr, P., Hlatky, M. A., Fosbøl, E. L., Køber, L., Torp-Pedersen, C. T., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100308 · Cited by 53
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Precision medicine for cardiometabolic disease: a framework for clinical translation
Franks, P. W., Cefalu, W. T., Dennis, J., Florez, J. C., Mathieu, C., Morton, R. W., Ridderstråle, M., Sillesen, H. H., & Stehouwer, C. D. A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00165-1 · Cited by 57
Self-citationSGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Piperidou, A., Loutradis, C., & Sarafidis, P. A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00393-4 · Cited by 50
Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 56
AlAufi, N. S., Chan, Y. M., Waly, M. I., Chin, Y. S., Yusof, B. N. M., & Ahmad, N. (2022) · Nutrients · doi:10.3390/nu14132777 · Cited by 52
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 60
Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4162 · Cited by 49
Monami, M., Candido, R., Pintaudi, B., Targher, G., Mannucci, E., Mannucci, E., Candido, R., Pintaudi, B., Targher, G., Monache, L. D., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.031 · Cited by 50
Xie, Y., Bowe, B. C., Gibson, A. K., McGill, J. B., Maddukuri, G. S., & Al‐Aly, Z. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2488 · Cited by 49
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
Boursier, J., Anty, R., Carette, C., Cariou, B., Castéra, L., Caussy, C., Fontaine, H., Garioud, A., Gourdy, P., Guerci, B., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101272 · Cited by 51
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 54
Microbial regulation of enteroendocrine cells
Arora, T., Vanslette, A. M., Hjorth, S. A., & Bäckhed, F. (2021) · Med · doi:10.1016/j.medj.2021.03.018 · Cited by 52
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 48
Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Subramanian, T., Kurian, S. J., Miraj, S. S., Rao, M., Raut, A. A., Kanwar, R. K., Singh, J., et al. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s329787 · Cited by 60
Brazilian Academy of Neurology practice guidelines for stroke rehabilitation: part I
Minelli, C., Bazán, R., Pedatella, M. T. A., Neves, L. D. O., Cacho, R. D. O., Magalhães, S. C. S. A., Luvizutto, G. J., Moro, C. H. C., Lange, M. C., Módolo, G. P., et al. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2021-0354 · Cited by 56
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 52
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Jeong, S. J., Lee, S. E., Shin, D. H., Park, I. B., Lee, H. S., & Kim, K. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02381-3 · Cited by 49
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01209-y · Cited by 48
Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 51
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Dąbrowski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041680 · Cited by 50
Luca, M. D., Zese, M., Bandini, G., Chiappetta, S., Iossa, A., Merola, G., Piatto, G., Tolone, S., Vitiello, A., Silverii, G. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15117 · Cited by 54
Rudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Sinha, B., & Ghosal, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-72967-8 · Cited by 46
Prevalencia de diabetes, características epidemiológicas y complicaciones vasculares
Russo, M. P., Ratti, M. F. G., Burgos, M. A., Molaro, A. A., & Bonella, M. B. (2023) · Archivos de cardiología de México · doi:10.24875/acm.21000410 · Cited by 90
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 47
Self-citationBecher, P. M., Schrage, B., Ferrannini, G., Benson, L., Butler, J., Carrero, J. J., Cosentino, F., Dahlström, U., Mellbin, L., Rosano, G. M. C., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2131 · Cited by 46
Metformin for pregnancy and beyond: the pros and cons
Newman, C., & Dunne, F. (2021) · Diabetic Medicine · doi:10.1111/dme.14700 · Cited by 46
Abedini, A., Sánchez-Navaro, A., Wu, J., Klötzer, K. A., Ma, Z., Poudel, B., Doke, T., Balzer, M. S., Frederick, J., Černecká, H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci157165 · Cited by 45
D’Andrea, E., Kesselheim, A. S., Franklin, J. M., Jung, E. H., Hey, S. P., & Patorno, E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01133-1 · Cited by 46
Greiver, M., Havard, A., Bowles, J., Kalia, S., Chen, T., Aliarzadeh, B., Moineddin, R., Sherlock, J., Hinton, W., Sullivan, F., et al. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x714089 · Cited by 45
Establishment of the SingHealth Diabetes Registry
Lim, D. Y. Z., Chia, S. Y., Kadir, H. B. A., Salim, N. N. M., & Bee, Y. M. (2021) · Clinical Epidemiology · doi:10.2147/clep.s300663 · Cited by 44
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01572-y · Cited by 48
Inzucchi, S. E., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00308-4 · Cited by 51
Zhang, X., Zhang, J., Ren, Y., Sun, R., & Zhai, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1368481 · Cited by 53
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 44
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Sebastián-Martín, A., Sánchez, B. G., Mora-Rodríguez, J. M., Bort, A., & Díaz‐Laviada, I. (2022) · Biomedicines · doi:10.3390/biomedicines10082026 · Cited by 48
Suzuki, Y., Kaneko, H., Okada, A., Matsuoka, S., Fujiu, K., Michihata, N., Jo, T., Takeda, N., Morita, H., Node, K., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.031 · Cited by 44
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 44
Current trends in diabetes mellitus database research in Japan
Kohsaka, S., Morita, N., Okami, S., Kidani, Y., & Yajima, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14325 · Cited by 43
Xu-bin, W., Wei, W., Ding, L., & Liu, S.-Y. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.08.017 · Cited by 41
Mata‐Cases, M., Vlacho, B., Real, J., Puig-Treserra, R., Bundó, M., Franch‐Nadal, J., & Mauricio, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.810757 · Cited by 43
Khunti, K., Jabbour, S. A., Cos, X., Mudaliar, S. R. D., Mende, C. W., Bonaca, M. P., & Fioretto, P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14684 · Cited by 42
Diabetes and the Risk of Sudden Cardiac Death
Svane, J., Pedersen‐Bjergaard, U., & Tfelt‐Hansen, J. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01366-2 · Cited by 45
Artime, E., Romera, I., Díaz‐Cerezo, S., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01060-8 · Cited by 45
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 43
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40
Lim, C.-E., Pasternak, B., Eliasson, B., Danaei, G., & Ueda, P. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac315 · Cited by 40
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Self-citationKim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 41
Buse, J. B., Bode, B. W., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Nielsen, M. A., & Pieber, T. R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001649 · Cited by 38
Self-citationInvited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 39
Diabetic kidney disease treatment: new perspectives
Tong, L., & Adler, S. G. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.288 · Cited by 42
Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37
Self-citationRastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
Bourdel‐Marchasson, I., Maggi, S., Abdelhafiz, A. H., Bellary, S., Demurtas, J., Forbes, A., Ivory, P., Rodríguez‐Mañas, L., Sieber, C. C., Strandberg, T. E., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02519-3 · Cited by 39
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif, T. E., Yibirin, M., Oliveira-Gomes, D. D., Machaalani, M., Nawfal, R., Carlini, G. B., Bahmad, H. F., & Bitar, N. (2022) · Cancers · doi:10.3390/cancers14092105 · Cited by 39
Alorfi, N. M., & Algarni, A. S. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s374741 · Cited by 42
Cromer, S. J., Lauffenburger, J. C., Levin, R., & Patorno, E. (2023) · Diabetes Care · doi:10.2337/dc22-0383 · Cited by 36
Scheen, A. J. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193528 · Cited by 35
Rao, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01989-z · Cited by 38
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Metadata
- Authors
- Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of Copenhagen (DK)
- Università Cattolica del Sacro Cuore (IT)
- Universitair Ziekenhuis Leuven (BE)
- Duke University (US)
- University of Leicester (GB)
- Corresponding author
- Davies, Melanie J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-19
- Volume
- 43
- Issue
- 2
- Pages
- 487-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6971782
- OpenAlex
- W4253996779
- Cited by
- 1,192
- References
- 21
- Citations by year
- 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
- FWCI
- 155.76
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-07-01)
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- Lirias (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- European Association for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
